OLMA News and Press, Olema Pharmaceuticals Inc. From 05/14/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Olema Pharmaceuticals (OLMA): Q1 GAAP EPS of -$0.39 misses by $0.11.Cash, cash equivalents and marketable securities of $326.97M.Press Release For further details see: Olema Pharmaceuticals EPS misses by $0.11

OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial in patients with metastatic, ER+ / HER2- breast cancer; Initial data anticipated in 2H 2021 Cash, cash equivalents, and marketable securities of $327.0 million as of March 31, 2021 sufficient to fu...

The following slide deck was published by Olema Pharmaceuticals, Inc. in conjunction with this event. For further details see: Olema Pharmaceuticals (OLMA) Investor Presentation - Slideshow

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womenȁ...

Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chai...

Gainers: Seneca Biopharma (SNCA) +25%, DarioHealth (DRIO) +25%, Dyadic International DYAI +24%, Marker Therapeutics (MRKR) +19%, Immunocore Holdings (IMCR) +11%.Losers: Odonate Therapeutics ODT -76%, Foghorn Therapeutics (FHTX) -13%,...

Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals (INFI) +13%.Losers: Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%, Lipocine (LPCN...

Olema Pharmaceuticals (OLMA): Q4 GAAP EPS of -$0.50.Cash and cash equivalents as of December 31, 2020 were $338.5 million. The company anticipates that the year-end balance of cash will be sufficient to fund operations through 2022.Press Release For further details see: Olema Pharmaceut...

Advancing OP-1250 in metastatic, ER+ / HER2- breast cancer Phase 1/2 clinical trial Clinical trial agreements announced with Novartis and Pfizer to explore combination of OP-1250 with CDK4/6 inhibitors and PI3Kα inhibitor Approximately $382 million in gross proc...